Lucid Competitors
| LUCD Stock | USD 1.19 0.05 4.39% |
Lucid Diagnostics vs Scilex Holding Correlation
Very good diversification
The correlation between Lucid Diagnostics and SCLX is -0.44 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Lucid Diagnostics and SCLX in the same portfolio, assuming nothing else is changed.
Moving against Lucid Stock
As of January 30, 2026, Return On Tangible Assets is expected to decline to -1.44. The current year's Return On Capital Employed is expected to grow to -5.48. The current year's Net Tangible Assets is expected to grow to about 23.7 M, whereas Total Assets are forecasted to decline to about 24 M.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lucid Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lucid Diagnostics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Lucid Diagnostics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Lucid and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Lucid Diagnostics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Lucid Stock performing well and Lucid Diagnostics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Lucid Diagnostics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RPID | 4.36 | 0.83 | 0.21 | 0.94 | 3.40 | 12.73 | 27.74 | |||
| APYX | 3.10 | 0.57 | 0.16 | 13.12 | 2.65 | 8.27 | 21.53 | |||
| RCEL | 2.55 | 0.17 | 0.05 | 0.39 | 2.42 | 6.67 | 16.25 | |||
| IRD | 3.39 | 0.49 | 0.12 | 0.56 | 3.55 | 7.62 | 26.50 | |||
| STSS | 5.62 | (1.19) | 0.00 | (0.39) | 0.00 | 10.34 | 39.53 | |||
| AVR | 3.90 | 0.38 | 0.10 | 0.34 | 3.55 | 9.42 | 25.09 | |||
| SEER | 1.46 | (0.21) | 0.00 | 2.68 | 0.00 | 3.41 | 9.98 | |||
| OWLT | 3.79 | 0.58 | 0.12 | 2.39 | 4.34 | 8.21 | 24.32 | |||
| IXHL | 4.01 | (0.17) | 0.00 | (0.02) | 0.00 | 11.76 | 26.74 | |||
| SCLX | 4.43 | (0.86) | 0.00 | (0.49) | 0.00 | 10.41 | 30.71 |
Cross Equities Net Income Analysis
Compare Lucid Diagnostics and related stocks such as Rapid Micro Biosystems, Apyx Medical, and Avita Medical Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPID | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (37.1 M) | (73.5 M) | (60.8 M) | (52.5 M) | (46.9 M) | (42.2 M) | (44.3 M) |
| APYX | (154.1 K) | 109 K | 617 K | (4.3 M) | (17.3 M) | (5.4 M) | (4 M) | (5.1 M) | 64 M | (19.7 M) | (11.9 M) | (15.2 M) | (23.2 M) | (18.7 M) | (23.5 M) | (21.1 M) | (20.1 M) |
| RCEL | (225.5 K) | (7.6 M) | (8.1 M) | (5.1 M) | (7.9 M) | (10.3 M) | (11.5 M) | (17.2 M) | (24.6 M) | (24.6 M) | (24.6 M) | (25.1 M) | (26.7 M) | (35.4 M) | (61.8 M) | (55.7 M) | (52.9 M) |
| IRD | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (24.6 M) | (56.7 M) | 17.9 M | (10 M) | (57.5 M) | (51.8 M) | (49.2 M) |
| STSS | (3.3 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.3 M) | (4.7 M) | (4.6 M) | (9.8 M) | (9.3 M) | (8.4 M) | (7.9 M) |
| AVR | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (17.2 M) | (30.6 M) | (46 M) | (76.3 M) | (68.7 M) | (65.2 M) |
| SEER | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (16 M) | (32.8 M) | (71.2 M) | (93 M) | (86.3 M) | (86.6 M) | (77.9 M) | (81.8 M) |
| OWLT | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (10.5 M) | (71.7 M) | (79.3 M) | (32.9 M) | (12.5 M) | (11.3 M) | (11.8 M) |
| IXHL | (179 K) | (3.2 M) | (11 M) | (11.3 M) | (1.9 M) | (591.9 K) | (15.9 M) | (2.2 M) | (1.9 M) | (3.2 M) | (8.2 M) | (10.3 M) | (48.8 M) | (27.6 M) | (46.9 M) | (42.2 M) | (40.1 M) |
| SCLX | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (47.5 M) | (88.4 M) | (23.4 M) | (114.3 M) | (72.8 M) | (83.7 M) | (87.9 M) |
Lucid Diagnostics and related stocks such as Rapid Micro Biosystems, Apyx Medical, and Avita Medical Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Lucid Diagnostics financial statement analysis. It represents the amount of money remaining after all of Lucid Diagnostics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Lucid Diagnostics Competitive Analysis
The better you understand Lucid Diagnostics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Lucid Diagnostics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Lucid Diagnostics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Lucid Diagnostics Competition Performance Charts
Five steps to successful analysis of Lucid Diagnostics Competition
Lucid Diagnostics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Lucid Diagnostics in relation to its competition. Lucid Diagnostics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Lucid Diagnostics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Lucid Diagnostics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Lucid Diagnostics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Lucid Diagnostics position
In addition to having Lucid Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cryptocurrency Thematic Idea Now
Cryptocurrency
Dynamically computed list of top cryptocurrencies sorted bymarket capitalization. The Cryptocurrency theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Lucid Diagnostics Correlation with its peers. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Will Health Care Equipment & Supplies sector continue expanding? Could Lucid diversify its offerings? Factors like these will boost the valuation of Lucid Diagnostics. Expected growth trajectory for Lucid significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lucid Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth 0.033 | Return On Assets | Return On Equity |
Understanding Lucid Diagnostics requires distinguishing between market price and book value, where the latter reflects Lucid's accounting equity. The concept of intrinsic value—what Lucid Diagnostics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lucid Diagnostics' price substantially above or below its fundamental value.
Understanding that Lucid Diagnostics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lucid Diagnostics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lucid Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.